Dian Diagnostics Group Co.,Ltd. (SHE:300244)
China · Delayed Price · Currency is CNY 18.96
+0.01 (0.05%)
Apr 28, 2026, 3:13 PM CST
Dian Diagnostics Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 10,096 | 12,196 | 13,407 | 20,281 | 13,079 |
Other Revenue | - | 0.37 | 1.36 | 1.71 | 3.6 |
| 10,096 | 12,196 | 13,408 | 20,282 | 13,083 | |
Revenue Growth (YoY) | -17.22% | -9.04% | -33.89% | 55.03% | 22.85% |
Cost of Revenue | 7,222 | 8,811 | 9,256 | 12,809 | 8,100 |
Gross Profit | 2,874 | 3,385 | 4,152 | 7,473 | 4,983 |
Selling, General & Admin | 1,874 | 2,049 | 2,300 | 2,834 | 2,296 |
Research & Development | 254.54 | 305.88 | 432.64 | 638.47 | 424.75 |
Other Operating Expenses | 3.5 | 39.36 | 30.44 | 56.17 | 44.65 |
Operating Expenses | 2,132 | 2,839 | 3,139 | 3,817 | 2,856 |
Operating Income | 741.48 | 546.34 | 1,013 | 3,657 | 2,127 |
Interest Expense | - | -203.03 | -250.6 | -274.73 | -230.2 |
Interest & Investment Income | 26.19 | 64.38 | 41.76 | 69.62 | 77.47 |
Currency Exchange Gain (Loss) | - | -2.02 | 0.84 | -25.12 | -2.33 |
Other Non Operating Income (Expenses) | -418.54 | -35.57 | -24.48 | -38.46 | -15.49 |
EBT Excluding Unusual Items | 349.13 | 370.11 | 780.65 | 3,388 | 1,956 |
Impairment of Goodwill | - | -377.97 | - | -589.64 | - |
Gain (Loss) on Sale of Investments | 3.53 | -28.72 | -18.32 | -56.24 | -187.72 |
Gain (Loss) on Sale of Assets | -0.18 | -1.48 | -3.57 | -11.18 | 6.35 |
Asset Writedown | -96.29 | -13.14 | -25.72 | -242.16 | -21.53 |
Legal Settlements | - | - | - | - | -7.59 |
Other Unusual Items | - | -0.63 | 65.29 | 54.74 | 45.1 |
Pretax Income | 256.19 | -51.83 | 798.33 | 2,544 | 1,791 |
Income Tax Expense | 110.58 | 117.41 | 216.74 | 681.09 | 307.4 |
Earnings From Continuing Operations | 145.61 | -169.23 | 581.59 | 1,862 | 1,484 |
Minority Interest in Earnings | -101.55 | -188.04 | -274.13 | -428.28 | -320.72 |
Net Income | 44.05 | -357.28 | 307.46 | 1,434 | 1,163 |
Net Income to Common | 44.05 | -357.28 | 307.46 | 1,434 | 1,163 |
Net Income Growth | - | - | -78.56% | 23.33% | 44.83% |
Shares Outstanding (Basic) | 611 | 617 | 625 | 623 | 620 |
Shares Outstanding (Diluted) | 611 | 617 | 625 | 624 | 624 |
Shares Change (YoY) | -0.98% | -1.30% | 0.18% | -0.02% | 0.43% |
EPS (Basic) | 0.07 | -0.58 | 0.49 | 2.30 | 1.87 |
EPS (Diluted) | 0.07 | -0.58 | 0.49 | 2.30 | 1.86 |
EPS Growth | - | - | -78.60% | 23.36% | 44.21% |
Free Cash Flow | 1,743 | 844.2 | 1,220 | 691.64 | 728.42 |
Free Cash Flow Per Share | 2.85 | 1.37 | 1.95 | 1.11 | 1.17 |
Dividend Per Share | - | 0.900 | 0.060 | 0.200 | 0.135 |
Dividend Growth | - | 1400.00% | -70.00% | 48.15% | 3.85% |
Gross Margin | 28.46% | 27.75% | 30.97% | 36.85% | 38.09% |
Operating Margin | 7.34% | 4.48% | 7.56% | 18.03% | 16.26% |
Profit Margin | 0.44% | -2.93% | 2.29% | 7.07% | 8.89% |
Free Cash Flow Margin | 17.26% | 6.92% | 9.10% | 3.41% | 5.57% |
EBITDA | 1,041 | 928.27 | 1,467 | 4,247 | 2,468 |
EBITDA Margin | 10.31% | 7.61% | 10.94% | 20.94% | 18.87% |
D&A For EBITDA | 299.3 | 381.92 | 453.51 | 590.21 | 341.57 |
EBIT | 741.48 | 546.34 | 1,013 | 3,657 | 2,127 |
EBIT Margin | 7.34% | 4.48% | 7.56% | 18.03% | 16.26% |
Effective Tax Rate | 43.16% | - | 27.15% | 26.78% | 17.16% |
Revenue as Reported | - | 12,196 | 13,408 | 20,282 | 13,083 |
Advertising Expenses | - | 59.27 | 68.34 | 76.59 | 59.74 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.